Filing Flows › Foghorn Therapeutics (FHTX) › Recalls, complaints & regulation
Foghorn Therapeutics (FHTX): clinical trials
Foghorn Therapeutics (FHTX) beyond its filings: 1 active clinical trial.
Foghorn Therapeutics' latest quarter
Foghorn Therapeutics, Q2 2026: revenue $16.1M (+113% year over year), operating margin -54.8%, net loss $7.2M, operating cash flow −$17.8M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Foghorn Therapeutics have?
1 active study on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.